Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1836159 | 0.95 | THRA (0.63) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1836108 | 0.94 | THRA (0.66) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1836935 | 0.94 | THRA (0.66) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1837530 | 0.94 | THRA (0.66) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1835055 | 0.94 | THRA (0.66) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1841440 | 0.94 | THRA (0.66) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL29416629 | 0.92 | THRA (0.61) | THRATHRBKDM4EMTNR1AMTNR1B | |
| SCHEMBL728259 | 0.92 | THRA (0.61) | THRATHRBKDM4EMTNR1AMTNR1B | |
| SCHEMBL1836742 | 0.90 | KDM4E (0.53) | THRATHRBKDM4EHPGDHSD17B10 | |
| SCHEMBL1838944 | 0.89 | THRA (0.67) | THRATHRBPPARAALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-3838892-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2022-10-12 | — | — | EP | disclosed |
| EP-3293173-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-07-28 | — | — | EP | disclosed |
| EP-3838892-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2021-06-23 | — | — | EP | disclosed |
| EP-2980066-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3440057-A1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | Proteostasis Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3153499-B1 | METHOD FOR PRODUCING N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3293173-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2018-03-14 | — | — | EP | disclosed |
| WO-2017177124-A1 | SILICONE ATOMS CONTAINING IVACAFTOR ANALOGUES | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-8884047-B2 | N-substituted carbamic acid ester production method and isocyanate production method using the N-substituted carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140194650-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8658819-B2 | N-substituted carbamic acid ester production method, isocyanate production method using such N-substituted carbamic acid ester, and composition for transfer and storage of N-substituted carbamic acid ester comprising N-substituted carbamic acid ester and aromatic hydroxy compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8476442-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
| US-4681900-A | POLYPROPYLENE GLYCOL-TRIGLYCERIDE-ALCOHOL REACTION PRODUCT | KAO CORPORATION (JP) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | THRA 4461/4885THRB 4723/4885KDM4E 375/4885 |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | THRA 3722/4885THRB 3044/4885KDM4E 3089/4885 |
| US-20140194650-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | THRA 4461/4885THRB 4723/4885KDM4E 375/4885 |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | THRA 2001/4885THRB 2483/4885KDM4E 232/4885 |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | THRA 4461/4885THRB 4723/4885KDM4E 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.